Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia - Seite 2

Novartis is supporting the campaign financially and has pledged to match up to 1 million treatments funded by the public every year through 2015. For more than a decade, the Novartis Malaria Initiative has worked to improve access to treatment, help communities deliver better healthcare and has invested in research and development into the next generation of antimalarials. Since 2009, Novartis has delivered over 600 million treatments, of which more than 200 million were treatments developed specifically for children, without profit to malaria-endemic countries. Never before have so many pediatric treatments been distributed in such a short timeframe to children suffering from malaria[3].

About Power of One
Malaria No More's Power of One campaign offers the global public and corporations the opportunity to help end malaria deaths one dollar and one child at a time. Every dollar donated funds a full treatment course for a child diagnosed with malaria in Africa. Malaria No More is grateful for the support and contributions of Power of One partners: Novartis, Alere, the Zambian Government, 21st Century Fox, AGFUND, AHAlife.com, the Bill & Melinda Gates Foundation, Causes.com, Havas Worldwide, John Snow, Inc., Newman's Own Foundation, PATH/MACEPA, Peace Corps, Time Warner, Twitter, the United States President's Malaria Initiative, Venmo, West, and more. Additional information is available at www.Po1.org.

About the Novartis Malaria Initiative
The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to working towards malaria elimination by driving the development of next-generation antimalarials, with two new classes of drugs currently in clinical development. The most advanced compound is in Phase II clinical trials. For more information, please visit: www.malaria.novartis.com

Disclaimer
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "expects," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.